EARS - Auris Medical

Discussion in 'Penny Stocks' started by KyleLennon, Aug 17, 2018.

  1. KyleLennon

    KyleLennon Member

    Joined:
    Mar 25, 2018
    Messages:
    248
    Likes Received:
    34
    [​IMG]


    Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
     
    T0rm3nted likes this.
  2. KyleLennon

    KyleLennon Member

    Joined:
    Mar 25, 2018
    Messages:
    248
    Likes Received:
    34
    Auris Medical is a clinical-stage biotech company developing therapeutics for neurotology and mental health supportive care. The stock is down 85% since peaking in April at $1.81. Keep in mind, the company generates a net loss of $3.1 million, and it hasn't produced a penny of revenue yet.
     

Share This Page